Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CG Oncology, Inc.CGON · Entity 3735 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CG Oncology, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Seven Fleet Partners LP | 1,886,236 |
Reported balance
After 2026-06-25 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-25 · Purchase · Acquired 371,085 · Balance 1,886,236 F1: The Reporting Person, as the managing member of Seven Fleet Advisors, LLC, the investment manager of Seven Fleet Partners, LP, may be deemed to beneficially own the shares of Common Stock held by Seven Fleet Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person, as the managing member of Seven Fleet Advisors, LLC, the investment manager of Seven Fleet Partners, LP, may be deemed to beneficially own the shares of Common Stock held by Seven Fleet Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 21:26 UTC | CG Oncology, Inc. CGON · Entity 3735 | PurchaseCommon Stock | 371,085 | $66.87 | $24,814,453.95 |
DisclosureSEC source: 0001140361-26-026779 · form4.xml · nonDerivative · entry 1 Liu Brian Guan-Chyun · CIK 0002007835 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Seven Fleet Partners LP Disclosed balance after: 1,886,236 F1 · ownership.direct: The Reporting Person, as the managing member of Seven Fleet Advisors, LLC, the investment manager of Seven Fleet Partners, LP, may be deemed to beneficially own the shares of Common Stock held by Seven Fleet Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantDirector Stock Option (right to buy) · Derivative | 9,354 | $0.00 Strike: $56.09 | $0.00 |
DisclosureSEC source: 0001193125-26-259700 · ownership.xml · derivative · entry 1 Liu Brian Guan-Chyun · CIK 0002007835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,354 Underlying: Common Stock · 9,354 shares Expires 2036-06-03 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 12:32 UTC | CG Oncology, Inc. CGON · Entity 3735 | PurchaseCommon Stock | 1,515,151 | $33.00 | $49,999,983.00 |
DisclosureSEC source: 0001193125-25-202873 · ownership.xml · nonDerivative · entry 1 Liu Brian Guan-Chyun · CIK 0002007835 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Seven Fleet Partners LP Disclosed balance after: 1,515,151 F1 · ownership.nature: The Reporting Person, as the managing member of Seven Fleet Advisors, LLC, the investment manager of Seven Fleet Partners, LP, may be deemed to beneficially own the shares of Common Stock held by Seven Fleet Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:00 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantDirector Stock Option (right to buy) · Derivative | 24,165 | $0.00 Strike: $26.63 | $0.00 |
DisclosureSEC source: 0000950170-25-083237 · ownership.xml · derivative · entry 1 Liu Brian Guan-Chyun · CIK 0002007835 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,165 Underlying: Common Stock · 24,165 shares Expires 2035-06-04 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 5, 2025, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 21:08 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantStock Option (Right to Buy) · Derivative | 15,600 | $0.00 Strike: $36.63 | $0.00 |
DisclosureSEC source: 0000950170-24-113311 · ownership.xml · derivative · entry 1 Liu Brian Guan-Chyun · CIK 0002007835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,600 Underlying: Common Stock · 15,600 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following October 4, 2024, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.